Assertio Holdings, Inc. (ASRT)

0,7730 +0,0190 (+2,52%) Al cierre: 04:00PM EDT

Assertio Holdings, Inc.

100 South Saunders Road
Suite 300
Lake Forest, IL 60045
United States
224 419 7106
https://www.assertiotx.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 53

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Ms. Heather L. Mason	Interim CEO & Director	92,5k	N/A	1960
Mr. Ajay Patel	Senior VP & CFO	742,01k	N/A	1985
Mr. Paul Schwichtenberg	Senior Vice President & Chief Commercial Officer	780,88k	N/A	1972
Mr. Bill Iskos	Senior Vice President of Operations	N/A	N/A	N/A
Ms. Molly Dir	Senior Vice President of HR & Administration ?	N/A	N/A	N/A
Mr. Sam Schlessinger	Senior VP & General Counsel	N/A	N/A	N/A
Dr. Howard J. Franklin M.B.A., M.D.	Senior Vice President of Medical	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Gobierno corporativo

El ISS Governance QualityScore de Assertio Holdings, Inc., a día 1 de abril de 2024, es 2. Las puntuaciones base son Auditoría: 6; Tablero: 5; Derechos de los accionistas: 1; Compensación: 3.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.